The enhanced oncogenic potential of RAS mutations after inactivation of the oncogenic JAK/STAT pathway illuminates an intriguing paradoxical oncogenic mechanism, highlights the complexity of the cancer combinatorial mutational landscape and challenges our current approach to targeted therapy use in cancer. The gene discussed is SOAT1; the disease is cancer.